Pfizer’s Deal Desires Move From Drug Pipeline to Products
This article is for subscribers only.
Pfizer Inc. is still hunting for a deal, even as the target changes.
Chief Executive Officer Ian Read signaled as much Tuesday, saying on a conference call that the company is “biased toward deals with the potential for creating value in the near term.” That means buying assets that can boost sales and eliminate costs quickly, rather than acquisitions for long-term drug development.